{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T20:43:39Z","timestamp":1777063419586,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institute of Health","award":["5K-12 CA090625-09"],"award-info":[{"award-number":["5K-12 CA090625-09"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.clml.2012.07.003","type":"journal-article","created":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T03:02:10Z","timestamp":1347591730000},"page":"406-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Superior Long-Term Outcome of Patients With Early Transformation of Non-Hodgkin Lymphoma Undergoing Stem Cell Transplantation"],"prefix":"10.1016","volume":"12","author":[{"given":"Nishitha","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madan H.","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.07.003_bib1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/asheducation.V2009.1.532.532","article-title":"The incidence, natural history, biology, and treatment of transformed lymphomas","author":"Bernstein","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2012.07.003_bib2","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib3","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3109\/10428194.2010.497981","article-title":"Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma","volume":"51","author":"Clavert","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.07.003_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2011.05.002","article-title":"Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach","volume":"17","author":"Reddy","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2012.07.003_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2012.07.003_bib6","first-page":"790","article-title":"Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma [Abstract]","volume":"110","author":"Al-Tourah","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.07.003_bib7","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2004.06.055","article-title":"Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma","volume":"22","author":"Davies","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib8","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib9","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"18","author":"Vose","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib10","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1200\/JCO.2006.07.5671","article-title":"Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis","volume":"24","author":"Ghesqui\u00e8res","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib11","first-page":"114","article-title":"Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas","volume":"91","author":"Cilley","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.07.003_bib12","first-page":"1236","article-title":"Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation","volume":"90","author":"Barosi","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.07.003_bib13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2141.2010.08519.x","article-title":"High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas","volume":"152","author":"Eide","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.07.003_bib14","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.07.003_bib15","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/sj.leu.2404334","article-title":"Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents","volume":"20","author":"Barrett","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.07.003_bib16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The follicular lymphoma international prognostic index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gin\u00e9","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European bone marrow transplant registry","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","article-title":"Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma","volume":"131","author":"Doocey","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.07.003_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002770050503","article-title":"High-dose therapy and stem cell transplantation in follicular lymphoma","volume":"78","author":"Friedberg","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2012.07.003_bib21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbmt.2006.03.014","article-title":"Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy","volume":"12","author":"Gopal","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2012.07.003_bib22","first-page":"315","article-title":"Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL) [Abstract]","volume":"108","author":"Khouri","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.07.003_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/10428190500260478","article-title":"Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan","volume":"47","author":"Fietz","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.07.003_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.07.003_bib25","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.07.003_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","article-title":"The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin","volume":"154","author":"Czuczman","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501200136X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501200136X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:33Z","timestamp":1761870153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501200136X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S215226501200136X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.07.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Superior Long-Term Outcome of Patients With Early Transformation of Non-Hodgkin Lymphoma Undergoing Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}